Metabolic dysfunction-associated fatty liver disease, or MAFLD, is the most common chronic liver disease in the world, affecting an estimated 1.27 billion people as of 2021. The name itself is relatively new, adopted in 2020 to replace the older label “nonalcoholic fatty liver disease” (NAFLD), but the condition it describes is not: excess fat in the liver driven by metabolic problems like insulin resistance, obesity, and type 2 diabetes. What makes MAFLD worth understanding is that it is not just a liver problem. It reaches into nearly every organ system and is tied to heart disease, kidney disease, and several cancers.
Why the Name Changed
For decades, the standard term was NAFLD, which defined the condition by what it was not: fatty liver that was “nonalcoholic.” That framing had two practical problems. First, it required doctors to rule out every other possible cause of liver disease, including alcohol use, before making a diagnosis. That exclusionary process slowed things down and missed people who had both metabolic liver disease and another condition at the same time. Second, “nonalcoholic” carried a stigma implication, as though the patient needed to prove they did not drink. The MAFLD label flipped the approach. Instead of ruling things out, it requires ruling things in: evidence of fat in the liver plus at least one metabolic risk factor such as overweight, type 2 diabetes, or signs of metabolic dysfunction like elevated blood pressure or abnormal blood lipids.1PubMed Central. MAFLD: How is it different from NAFLD?
You may also encounter a third name, MASLD (metabolic dysfunction-associated steatotic liver disease), introduced in 2023 by a different consortium. In practice, the two newer labels capture almost identical patient populations. A study comparing all three frameworks found that about 97% of people who met the old NAFLD criteria also met MAFLD criteria, and a nearly identical 97.5% met MASLD criteria. A small group of lean patients with mild insulin resistance fell through the cracks of both new systems, highlighting a gap that researchers are still working to close.2PubMed Central. Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort
How Common MAFLD Is Around the World
The global numbers are staggering. About 1.27 billion MAFLD cases were reported worldwide in 2021, with an age-standardized prevalence rate of roughly 15,000 per 100,000 people.3PubMed Central. Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021 The disease does not spread evenly. North Africa and the Middle East have the highest prevalence at about 26%, and the fastest rate of increase. East Asia follows closely, with a prevalence around 20% and one of the steepest upward trends over recent decades. Central Latin America also stands out, with an age-standardized prevalence of about 17%.4PubMed Central. Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021 These regional differences mirror patterns in obesity, processed-food access, and urbanization, but genetics also play a role, as discussed below.
What Happens Inside the Liver
At the simplest level, MAFLD begins when the liver accumulates more fat than it can safely handle. When your body is resistant to insulin, circulating glucose and insulin levels stay elevated, and the liver responds by ramping up its own fat production, a process called de novo lipogenesis. Research has shown that this internal fat-making machinery is directly correlated with how insulin-resistant a person is, and that higher round-the-clock glucose and insulin levels drive it further.5PubMed Central. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
For many people, the disease stays at this “simple steatosis” stage, where fat sits in the liver without causing major damage. But in a substantial minority, the excess fat generates toxic lipid byproducts that injure liver cells, trigger inflammation, and activate cell-death pathways. This cascade of lipotoxicity is what pushes simple fatty liver into steatohepatitis, the inflamed, scarring form of the disease.6PubMed. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD) Once inflammation takes hold, specialized cells in the liver called stellate cells become activated and begin laying down scar tissue, or fibrosis. The behavior of these stellate cells largely dictates whether someone’s disease stabilizes, reverses, or progresses toward cirrhosis.7PubMed Central. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
The gut plays a role too. In people with fatty liver disease, bacteria from the intestine can migrate through the portal vein into the liver and trigger abnormal immune responses. The liver’s resulting inflammatory signals then damage the intestinal barrier in return, weakening the tight junctions between gut cells and allowing even more bacteria to cross over. This self-reinforcing liver-gut cycle can accelerate the progression from simple fat accumulation to active inflammation.8Journal of Clinical and Translational Hepatology. The Gut Microbiome and Ferroptosis in MAFLD
MAFLD Is Not Just a Liver Disease
The most common cause of death in people with MAFLD is not liver failure. It is cardiovascular disease. Shared mechanisms like insulin resistance, chronic low-grade inflammation, and oxidative stress link MAFLD to increased risk of coronary artery disease, heart failure, and ischemic heart disease.9PubMed Central. MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk This is why some hepatologists describe MAFLD as a metabolic disease that happens to show up most visibly in the liver.
The kidneys are also vulnerable. A meta-analysis of seven cohort studies found that people with MAFLD had about a 29% higher risk of developing chronic kidney disease over a median follow-up of six years.10PubMed Central. Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis One study went further and separated MAFLD from plain NAFLD, finding that the metabolic dysfunction component was the key driver of kidney risk. People who had liver fat plus metabolic dysfunction had nearly double the risk of kidney disease compared to those without either condition, while people who had liver fat alone without metabolic dysfunction showed no elevated kidney risk at all.11Scientific Reports. MAFLD and NAFLD in the prediction of incident chronic kidney disease
Cancer risk extends well beyond the liver. A large cohort study found that MAFLD was significantly associated with 10 of 24 specific cancers examined, including uterine, gallbladder, liver, kidney, thyroid, esophageal, pancreatic, bladder, breast, and colorectal cancers. The strongest associations were with uterine cancer, at more than twice the risk, and gallbladder cancer.12PubMed. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers A separate Chinese cohort confirmed elevated risks for prostate, thyroid, kidney, and breast cancers.13PubMed Central. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China These findings reinforce the idea that the systemic metabolic dysfunction underlying MAFLD creates a body-wide environment favorable to tumor development, not just a liver-specific one.
Liver Cancer Without Cirrhosis
Traditionally, doctors watched for liver cancer mainly in patients who had already developed cirrhosis. MAFLD has upended that thinking. Liver cancer can develop in people with fatty liver disease who have no cirrhosis at all. The transformation is driven by the same metabolic forces at work throughout the disease: lipotoxicity from fat-overloaded liver cells, oxidative stress, and immune dysfunction.14PubMed Central. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
Type 2 diabetes roughly doubles the risk of liver cancer, and obesity at a BMI above 35 quadruples it. When metabolic syndrome and diabetes are both present, the risk climbs to about five times the baseline.15Liver Cancer. The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology Researchers have developed a prediction model for liver cancer in people with fatty liver disease who do not have cirrhosis, using six readily available factors: age, sex, diabetes status, obesity, and two routine liver enzyme levels.16PubMed. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis The practical takeaway is that if you have MAFLD, screening conversations should not wait until cirrhosis appears on a scan.
Genetics and Who Gets Hit Hardest
Not everyone with obesity or insulin resistance develops severe liver disease, and genetics help explain why. Three gene variants in particular have been studied extensively. The PNPLA3 variant (rs738409) is the best established: carrying two copies roughly doubles the odds of developing steatohepatitis and raises the odds of significant fibrosis by about 50% beyond what metabolic risk factors alone would predict.17PubMed. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease When PNPLA3 was studied alongside the TM6SF2 and MBOAT7 variants, a clearer picture emerged: PNPLA3 influences both fat accumulation and fibrosis, TM6SF2 mainly drives fat accumulation, and MBOAT7 is more specifically linked to fibrosis.18Journal of Lipid Research. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study
These variants are additive: carrying risk alleles in more than one gene compounds the danger. A study that included the protective HSD17B13 variant found that people homozygous for the PNPLA3 risk allele had more than three times the odds of advanced fibrosis, while carrying the TM6SF2 risk allele nearly doubled the odds independently.19PubMed Central. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease These same variants also show up as risk factors for liver cancer in people without cirrhosis, further strengthening the case for genetic risk assessment in clinical practice.20Liver Cancer. The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology Genetic testing for these variants is not yet standard in most clinics, but it is increasingly used in research settings to stratify risk.
Diagnosing and Staging Without a Biopsy
Liver biopsy remains the technical gold standard for confirming steatohepatitis and grading fibrosis, but it is invasive, painful, and impractical for screening a billion-plus people worldwide. Noninvasive tools have gotten remarkably good. Vibration-controlled transient elastography (often known by the brand name FibroScan) is the most widely validated bedside test and works by measuring liver stiffness as a proxy for fibrosis. Point and two-dimensional shear-wave elastography perform comparably. But the most accurate noninvasive imaging tool available today is magnetic resonance elastography, or MRE, which has consistently achieved accuracy above 90% for detecting all stages of fibrosis.21Clinical and Molecular Hepatology. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future MRE’s main limitations are cost and availability; transient elastography is far more accessible in primary-care settings.
Blood-based markers are advancing too. Simple scoring systems like FIB-4 (which uses age, platelet count, and liver enzymes) are already used in primary care to flag patients who need further workup. On the research frontier, circulating microRNAs, tiny fragments of genetic material released by liver cells into the bloodstream, show promise as biomarkers. A handful of microRNAs, particularly miR-122, miR-34a, miR-21, and miR-192, are consistently elevated in people with fatty liver disease and correlate with disease severity.22PubMed. Circulating miRNAs associated with nonalcoholic fatty liver disease A panel combining four of these markers achieved diagnostic accuracy for steatohepatitis around 87.5%, which held up in external validation.23Scientific Reports. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease A recent case-control study confirmed that miR-34a was the single most predictive circulating marker, with miR-223 close behind.24The Egyptian Journal of Internal Medicine. Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: a case–control study These blood tests are not yet standard clinical tools, but they are moving in that direction.
Weight Loss and Diet Still Come First
Before any drug or procedure, the first-line treatment for MAFLD is lifestyle change. A weight reduction of 7 to 10% of body weight through calorie restriction and regular exercise is associated with meaningful improvement across the board: reduced liver fat, less inflammation, and even reversal of fibrosis.25PubMed Central. Mediterranean diet and nonalcoholic fatty liver disease The Mediterranean dietary pattern, rich in olive oil, fish, nuts, vegetables, and whole grains, has been studied extensively in this population and shows particular benefit, in part because it addresses insulin resistance and inflammation simultaneously.
The challenge, of course, is that sustained weight loss is notoriously difficult. That is where pharmacological and surgical options enter the picture, not as replacements for lifestyle change but as tools for patients who cannot achieve or maintain enough weight loss on their own.
Drug Therapies Gaining Ground
No drug has been universally approved specifically for MAFLD or its inflammatory subtype, though the landscape is shifting quickly. Two classes of medication are getting the most attention.
GLP-1 receptor agonists, the same drugs that have become household names for diabetes and weight loss, have shown meaningful effects on liver fat, inflammation, and fibrosis markers in patients with fatty liver disease.26PubMed Central. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives Evidence suggests these drugs can reverse steatohepatitis and reduce cardiovascular risk, which matters enormously given that heart disease is the leading killer in this population. They are not yet approved by the FDA specifically for liver disease, but they are available for obesity and type 2 diabetes, conditions that heavily overlap with MAFLD.27PubMed. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Dual receptor agonists, which target both GLP-1 and glucagon receptors, are also showing striking results in trials. Pemvidutide, a GLP-1/glucagon dual agonist, achieved relative reductions in liver fat content of up to about 69% at its middle dose after just 12 weeks, compared to a negligible 4% reduction with placebo. More than half of patients on the middle dose had their liver fat content normalize entirely to below 5%.28PubMed. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Thyroid hormone receptor-beta agonists represent another approach. Resmetirom (sold as Rezdiffra) became the first drug approved specifically for liver fibrosis due to steatohepatitis in the United States in 2024. Preclinical work on related compounds in this class, such as CS27109, has shown dose-dependent reductions in liver fat in animal models, with efficacy comparable to the lead compound in its class.29PubMed Central. CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models
Bariatric Surgery and Advanced Fibrosis
For patients with severe obesity and advanced liver disease, bariatric surgery offers the most dramatic results available. A meta-analysis found pooled remission rates of about 70% for steatohepatitis, 57% for fibrosis, and 59% for type 2 diabetes following bariatric procedures.30PubMed. Metabolic and bariatric surgery in MAFLD: a meta-analysis of endocrine outcomes, fibrosis remission, and postoperative complications
A landmark five-year follow-up study showed that steatohepatitis resolved in 84% of patients after bariatric surgery, with no worsening of fibrosis. Fibrosis decreased in about 70% of patients and disappeared entirely in 56%. Importantly, the improvement was durable: resolution seen at one year did not significantly recur between years one and five. The patients whose steatohepatitis persisted were those who lost the least weight, underscoring that the surgery’s benefit comes primarily through the metabolic changes driven by sustained weight loss.31PubMed. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis Even patients who started with bridging fibrosis, one stage short of cirrhosis, saw fibrosis disappear in about 45% of cases.
MAFLD in Children and Adolescents
MAFLD is not an adults-only disease. A systematic review and meta-analysis of overweight and obese children and adolescents found an overall prevalence of about 34% in the general population and 45% in children seen at obesity clinics. Boys are consistently more affected than girls, with prevalence roughly 36% versus 27% in community populations and 50% versus 35% in clinic populations.32PubMed Central. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis These numbers are alarming because they mean a generation is entering adulthood with decades of cumulative liver exposure ahead of them. The long-term consequences of childhood-onset MAFLD remain incompletely studied, but early intervention through dietary change and physical activity is the main strategy.
Sleep Apnea and MAFLD
One connection that often surprises people is the link between obstructive sleep apnea and MAFLD. In a study of patients evaluated for sleep disorders, the prevalence of MAFLD climbed steeply with sleep apnea severity: about 58% in those without sleep apnea, 72% in those with mild-to-moderate sleep apnea, and 78% in those with the severe form. After adjusting for confounders, the oxygen desaturation that occurs during apnea episodes independently predicted MAFLD.33PubMed Central. Association Between Metabolic-Associated Fatty Liver Disease and Obstructive Sleep Apnea: A Cross-Sectional Study A separate analysis combining observational data from a large U.S. population survey with genetic evidence from Mendelian randomization confirmed the association, finding that sleep apnea roughly doubled the odds of MAFLD even after adjusting for shared risk factors like obesity.34Nutrition, Metabolism and Cardiovascular Diseases. Obstructive sleep apnea and metabolic-associated fatty liver disease risk: Insights from National Health and Nutrition Examination Survey and Mendelian randomization analysis The likely mechanism is that repeated drops in oxygen during sleep episodes promote inflammation and insulin resistance, feeding directly into the metabolic cascade that drives liver fat accumulation. If you have been diagnosed with MAFLD and snore heavily or feel chronically unrested, a sleep evaluation is worth discussing with your doctor.
The Economic Weight of Advanced Disease
The financial burden of MAFLD concentrates heavily at the severe end of the disease spectrum. An analysis from a tertiary-care MAFLD clinic found that hospitalization was the single largest driver of healthcare costs, and patients with advanced fibrosis (stages F3 and F4) accounted for a disproportionately high share of spending.35PubMed Central. Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost analysis from a tertiary-care, multidisciplinary MAFLD clinic This pattern makes a strong case for early detection and intervention. Catching the disease before fibrosis advances is not only better for the patient but vastly cheaper for healthcare systems already straining under the weight of metabolic disease. The challenge is building integrated care models that address the liver, the metabolic syndrome, and the cardiovascular risk together rather than in separate specialist silos.